TY - JOUR
T1 - COVID-19 vaccination in autoimmune disease (COVAD) survey protocol
AU - COVAD Study Group
AU - Sen, Parikshit
AU - Gupta, Latika
AU - Lilleker, James B.
AU - Aggarwal, Vishwesh
AU - Kardes, Sinan
AU - Milchert, Marcin
AU - Gheita, Tamer
AU - Salim, Babur
AU - Velikova, Tsvetelina
AU - Gracia-Ramos, Abraham Edgar
AU - Parodis, Ioannis
AU - O’Callaghan, Albert Selva
AU - Nikiphorou, Elena
AU - Tan, Ai Lyn
AU - Cavagna, Lorenzo
AU - Saavedra, Miguel A.
AU - Shinjo, Samuel Katsuyuki
AU - Ziade, Nelly
AU - Knitza, Johannes
AU - Kuwana, Masataka
AU - Cagnotto, Giovanni
AU - Nune, Arvind
AU - Distler, Oliver
AU - Chinoy, Hector
AU - Aggarwal, Vikas
AU - Aggarwal, Rohit
AU - Barman, Bhupen
AU - Singh, Yogesh Preet
AU - Ranjan, Rajiv
AU - Jain, Avinash
AU - Pandya, Sapan C.
AU - Malaviya, A. N.
AU - Pilania, Rakesh Kumar
AU - Sharma, Aman
AU - Manoj, M. Manesh
AU - Gupta, Vikas
AU - Kavadichanda, Chengappa G.
AU - Patro, Pradeepta Sekhar
AU - Ajmani, Sajal
AU - Phatak, Sanat
AU - Goswami, Rudra Prosad
AU - Chowdhury, Abhra Chandra
AU - Mathew, Ashish Jacob
AU - Shenoy, Padnamabha
AU - Asranna, Ajay
AU - Bommakanti, Keerthi Talari
AU - Shukla, Anuj
AU - Naveen, R.
AU - Cansu, Döndü Üsküdar
AU - Kaneko, Yuko
N1 - Funding Information:
HC is supported by the National Institution for Health Research Manchester Biomedical Research Centre Funding Scheme. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health.
Publisher Copyright:
© 2021, Crown.
PY - 2022/1
Y1 - 2022/1
N2 - The coronavirus disease-2019 (COVID-19) pandemic continues to be a cause of unprecedented global morbidity and mortality. Whilst COVID-19 vaccination has emerged as the only tangible solution to reducing poor clinical outcomes, vaccine hesitancy continues to be an obstacle to achieving high levels of vaccine uptake. This represents particular risk to patients with autoimmune diseases, a group already at increased risk of hospitalization and poor clinical outcomes related to COVID-19 infection. Whilst there is a paucity of long-term safety and efficacy data of COVID-19 vaccination in patients with autoimmune diseases, the current evidence strongly suggests that the benefits of vaccination outweigh the risks of adverse effects and disease flares. Herein, we report the protocol of the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study, an ongoing international collaborative study involving 29 countries and over 110 investigators.
AB - The coronavirus disease-2019 (COVID-19) pandemic continues to be a cause of unprecedented global morbidity and mortality. Whilst COVID-19 vaccination has emerged as the only tangible solution to reducing poor clinical outcomes, vaccine hesitancy continues to be an obstacle to achieving high levels of vaccine uptake. This represents particular risk to patients with autoimmune diseases, a group already at increased risk of hospitalization and poor clinical outcomes related to COVID-19 infection. Whilst there is a paucity of long-term safety and efficacy data of COVID-19 vaccination in patients with autoimmune diseases, the current evidence strongly suggests that the benefits of vaccination outweigh the risks of adverse effects and disease flares. Herein, we report the protocol of the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study, an ongoing international collaborative study involving 29 countries and over 110 investigators.
KW - Autoimmune diseases
KW - COVAD
KW - COVID-19
KW - Survey
KW - Vaccination
UR - http://www.scopus.com/inward/record.url?scp=85123651276&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123651276&partnerID=8YFLogxK
U2 - 10.1007/s00296-021-05046-4
DO - 10.1007/s00296-021-05046-4
M3 - Article
C2 - 34779868
AN - SCOPUS:85123651276
SN - 0172-8172
VL - 42
SP - 23
EP - 29
JO - Rheumatology International
JF - Rheumatology International
IS - 1
ER -
